Colorectal Adenoma and CarcinomaRM-CAR-MRPNCT07683312
Recurrence Mechanisms of Colorectal Adenoma After Resection and a Multi-Omics Research Protocol
An observational study of Colorectal Adenoma and Carcinoma, run by Zhongshan Hospital Xiamen University.
Trial summary
We aim to establish a single-cell atlas of primary adenomas, recurrent adenomas, and paired normal mucosa, identify recurrence-associated cell subpopulations and transcriptional pathways, and construct a risk prediction model for recurrence (integrating multi-omics features and clinical variables). Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Colorectal Adenoma and Carcinoma
- How many people
- 30 participants
- Where
- No sites listed yet
- Study dates
- 27 Jun 2026to 30 Dec 2029
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patients who have undergone colonoscopy
Who may be able to join
- Patients with colorectal adenoma confirmed by initial endoscopic examination and pathological diagnosis.
Who cannot join
- Use of antibiotics within the past 2 weeks; Patients without colorectal adenoma; Patients with familial adenomatous polyposis; Patients with special dietary habits, such as vegetarians, alcoholics, binge eaters, or anorexic patients, etc.
About this study
We aim to establish a single-cell atlas of primary adenomas, recurrent adenomas, and paired normal mucosa, identify recurrence-associated cell subpopulations and transcriptional pathways, and construct a risk prediction model for recurrence (integrating multi-omics features and clinical variables). Ultimately, we propose a panel of biomarkers that can be used to optimize follow-up strategies and guide potential microbiome-based interventions.
Under the premise of meeting routine clinicopathological requirements, we will collect tissue samples from 30 patients with colorectal adenomas. Each collected adenoma sample will be divided into three equal portions for scRNA-seq, scATAC-seq, and microbiome diversity sequencing, respectively. Two years after sampling, enrolled patients will undergo follow-up colonoscopy. Those in whom adenomas are detected will be classified as the recurrence group, while those without adenomas will be classified as the non-recurrence group. Sequencing data will be jointly analyzed in conjunction with clinical medical records. The tissue specimens obtained will not affect routine diagnosis or treatment outcomes.
Read the detailed description
This study aims to: (1) establish a single-cell atlas of primary adenomas, recurrent adenomas, and paired normal mucosa, and identify recurrence-associated cell subpopulations and transcriptional pathways; (2) construct a recurrence risk prediction model integrating multi-omics features and clinical variables, and propose a panel of biomarkers for optimizing follow-up strategies and guiding potential microbiome-based interventions. The study plans to collect colorectal adenoma tissues from 30 patients who are first diagnosed by endoscopy. Each specimen will be equally divided into three portions for single-cell RNA sequencing (scRNA-seq), single-cell ATAC sequencing (scATAC-seq), and microbiome diversity sequencing. Two years after sampling, all enrolled patients will undergo follow-up colonoscopy; those found to have adenomas will be assigned to the recurrence group, while those without adenomas will be assigned to the non-recurrence group. By integrating multi-omics data for association analysis between the two groups, we aim to elucidate the key drivers of post-polypectomy recurrence, and explore whether there exists an interpretable causal chain linking host epigenetic status, cellular transcriptional programs, and mucosa-associated microbiota that can explain recurrence risk and yield translatable biomarkers. A total of 30 cases will be included. Inclusion criteria: patients with colorectal adenoma confirmed by initial endoscopic examination and pathology. Exclusion criteria: (1) use of antibiotics within the past two weeks; (2) patients without colorectal adenoma; (3) patients with familial adenomatous polyposis; (4) patients with special dietary habits such as vegetarianism, alcoholism, binge eating, or anorexia. Under the premise of meeting routine clinicopathological requirements, 30 colorectal adenoma tissue samples will be collected and each sample will be divided into three equal parts for scRNA-seq, scATAC-seq, and microbiome diversity sequencing. Two years after sampling, patients will undergo follow-up colonoscopy; those with adenomas detected will be classified as the recurrence group, and those without as the non-recurrence group. Through integrated multi-omics correlation analysis, a single-cell integrative atlas of "mucosal microbiota - host epigenome (scATAC) - transcriptome (scRNA)" will be constructed to decipher the key cell states, regulatory elements, and microenvironmental signals underlying post-adenomectomy recurrence, and to establish a multidimensional biomarker panel for risk stratification. Statistical analysis will be performed using SPSS 26.0. Univariate statistical tests will be applied to compare differences between groups. For normally distributed data, ANOVA (for multiple groups) and Student's t-test (for two groups) will be used; for non-normally distributed data, the Kruskal-Wallis H test (for multiple groups) and Mann-Whitney U test (for two groups) will be employed.
- Conditions
- Colorectal Adenoma and Carcinoma
- Medical subject headings
- Carcinoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| The study plans to collect colorectal adenoma tissues from 30 patients initially detected by endosco | The study plans to collect colorectal adenoma tissues from 30 patients initially detected by endoscopy, and perform scRNA-seq, scATAC-seq, and microbiome diversity sequencing on each sample, respectively. Two years after sampling, all enrolled patients will undergo follow-up colonoscopy; those found to have adenomas will be assigned to the recurrence group, while those without adenomas will be assigned to the non-recurrence group. By integrating multi-omics data for association analysis between the recurrence and non-recurrence groups, we aim to investigate the main driving factors of post-polypectomy recurrence, and to explore whether there exists an interpretable causal chain linking host epigenetic status, cellular transcriptional programs, and mucosa-associated microbiota that can explain recurrence risk and yield translatable biomarkers. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Multi-Omics Research Protocol on Recurrence Mechanisms After Colorectal Adenoma Resection
Whether Recurrence Occurred
Measured: December 2029
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jul 2026
- Study start27 Jun 2026 (estimated)
- Primary completion30 Aug 2029 (estimated)
- Study completion30 Dec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Colorectal Adenoma and CarcinomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Zhongshan Hospital Xiamen University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jianyin Zhou, Zhongshan Hospital Xiamen University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07683312
- Sponsor's protocol ID
- ZhongshanHXU
- Acronym
- RM-CAR-MRP
- Status last verified
- Jun 2026
- First submitted
- 28 Jun 2026
- Last updated
- 6 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Uncertain research data
Study at a glance
From the registry record, last updated by the sponsor on 6 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Recurrence Mechanisms of Colorectal Adenoma After Resection and a Multi-Omics Research Protocol
- ClinicalTrials.gov ID
- NCT07683312
- Acronym / sponsor ID
- RM-CAR-MRP / ZhongshanHXU
- Conditions
- Colorectal Adenoma and Carcinoma
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Zhongshan Hospital Xiamen UniversityUniversity, hospital or other
- Study start
- 27 Jun 2026 (estimated)
- Primary completion
- 30 Aug 2029 (estimated)
- Study completion
- 30 Dec 2029 (estimated)
- First posted
- 6 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
We aim to establish a single-cell atlas of primary adenomas, recurrent adenomas, and paired normal mucosa, identify recurrence-associated cell subpopulations and transcriptional pathways, and construct a risk prediction model for recurrence (integrating multi-omics features and clinical variables). Ultimately, we propose a panel of biomarkers that can be used to optimize follow-up strategies and guide potential microbiome-based interventions.
Under the premise of meeting routine clinicopathological requirements, we will collect tissue samples from 30 patients with colorectal adenomas. Each collected adenoma sample will be divided into three equal portions for scRNA-seq, scATAC-seq, and microbiome diversity sequencing, respectively. Two years after sampling, enrolled patients will undergo follow-up colonoscopy. Those in whom adenomas are detected will be classified as the recurrence group, while those without adenomas will be classified as the non-recurrence group. Sequencing data will be jointly analyzed in conjunction with clinical medical records. The tissue specimens obtained will not affect routine diagnosis or treatment outcomes.
Detailed description
This study aims to: (1) establish a single-cell atlas of primary adenomas, recurrent adenomas, and paired normal mucosa, and identify recurrence-associated cell subpopulations and transcriptional pathways; (2) construct a recurrence risk prediction model integrating multi-omics features and clinical variables, and propose a panel of biomarkers for optimizing follow-up strategies and guiding potential microbiome-based interventions. The study plans to collect colorectal adenoma tissues from 30 patients who are first diagnosed by endoscopy. Each specimen will be equally divided into three portions for single-cell RNA sequencing (scRNA-seq), single-cell ATAC sequencing (scATAC-seq), and microbiome diversity sequencing. Two years after sampling, all enrolled patients will undergo follow-up colonoscopy; those found to have adenomas will be assigned to the recurrence group, while those without adenomas will be assigned to the non-recurrence group. By integrating multi-omics data for association analysis between the two groups, we aim to elucidate the key drivers of post-polypectomy recurrence, and explore whether there exists an interpretable causal chain linking host epigenetic status, cellular transcriptional programs, and mucosa-associated microbiota that can explain recurrence risk and yield translatable biomarkers. A total of 30 cases will be included. Inclusion criteria: patients with colorectal adenoma confirmed by initial endoscopic examination and pathology. Exclusion criteria: (1) use of antibiotics within the past two weeks; (2) patients without colorectal adenoma; (3) patients with familial adenomatous polyposis; (4) patients with special dietary habits such as vegetarianism, alcoholism, binge eating, or anorexia. Under the premise of meeting routine clinicopathological requirements, 30 colorectal adenoma tissue samples will be collected and each sample will be divided into three equal parts for scRNA-seq, scATAC-seq, and microbiome diversity sequencing. Two years after sampling, patients will undergo follow-up colonoscopy; those with adenomas detected will be classified as the recurrence group, and those without as the non-recurrence group. Through integrated multi-omics correlation analysis, a single-cell integrative atlas of "mucosal microbiota - host epigenome (scATAC) - transcriptome (scRNA)" will be constructed to decipher the key cell states, regulatory elements, and microenvironmental signals underlying post-adenomectomy recurrence, and to establish a multidimensional biomarker panel for risk stratification. Statistical analysis will be performed using SPSS 26.0. Univariate statistical tests will be applied to compare differences between groups. For normally distributed data, ANOVA (for multiple groups) and Student's t-test (for two groups) will be used; for non-normally distributed data, the Kruskal-Wallis H test (for multiple groups) and Mann-Whitney U test (for two groups) will be employed.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| The study plans to collect colorectal adenoma tissues from 30 patients initially detected by endosco | – | –The study plans to collect colorectal adenoma tissues from 30 patients initially detected by endoscopy, and perform scRNA-seq, scATAC-seq, and microbiome diversity sequencing on each sample, respectively. Two years after sampling, all enrolled patients will undergo follow-up colonoscopy; those found to have adenomas will be assigned to the recurrence group, while those without adenomas will be assigned to the non-recurrence group. By integrating multi-omics data for association analysis between the recurrence and non-recurrence groups, we aim to investigate the main driving factors of post-polypectomy recurrence, and to explore whether there exists an interpretable causal chain linking host epigenetic status, cellular transcriptional programs, and mucosa-associated microbiota that can explain recurrence risk and yield translatable biomarkers. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients who have undergone colonoscopy
Key inclusion criteria (1 listed)
- Patients with colorectal adenoma confirmed by initial endoscopic examination and pathological diagnosis.
Key exclusion criteria (1 listed)
- Use of antibiotics within the past 2 weeks; Patients without colorectal adenoma; Patients with familial adenomatous polyposis; Patients with special dietary habits, such as vegetarians, alcoholics, binge eaters, or anorexic patients, etc.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Multi-Omics Research Protocol on Recurrence Mechanisms After Colorectal Adenoma Resection
Time frame: December 2029
Whether Recurrence Occurred
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Jul 2026.
- Individual participant dataSharing planned: Undecided. Uncertain research data
Related trials for Colorectal Adenoma and Carcinoma
Enrolling by invitationObservational study
Protein Signature Based Screening of Colorectal Adenomas and Cancer
Colorectal Cancer, Colorectal Adenoma
Active, not recruitingPhase 2
Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer
Colorectal Adenoma, Stage 0 Colorectal Cancer AJCC v8
Recruiting
Performance and Safety of MiWEndo-assisted Colonoscopy (MiWEndo II)
Colorectal Cancer, Colorectal Polyp
Recruiting
Colonoscopy vs Stool Testing for Older Adults With Colon Polyps
Colorectal Polyp, Colorectal Neoplasms
Active, not recruitingObservational study
Diagnostic Accuracy of a Panel of Bacterial Gene Markers (M3) for Colorectal Advanced Neoplasia
Colorectal Cancer, Colorectal Neoplasms
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Colorectal Adenoma and Carcinoma, run by Zhongshan Hospital Xiamen University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 6 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Multi-Omics Research Protocol on Recurrence Mechanisms After Colorectal Adenoma Resection (time frame: December 2029). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jul 2026; AzTrials last refreshed its copy on 7 Nov 2026.